Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Michael N. Neely, MD

    TitleAssociate Professor of Pediatrics (Clinical Scholar)
    SchoolKeck School of Medicine of USC
    AddressCHLA 4650 W. Sunset Blvd.
    Off Campus
    Los Angeles California 90026
    Phone+1 323 361 5047
    vCardDownload vCard
      Other Positions
      TitleCHLA Division Chief of Infectious Diseases

      Collapse Overview 
      Collapse Overview
      Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. Although Dr. Neely primarily works in the therapeutic area of infectious diseases on antiviral, antiretroviral and antifungal compounds, he has experience with other therapeutic areas. He is currently board certified in Pediatrics and Pediatric Infectious Diseases, and he is the co-Director of the Laboratory of Applied Pharmacokinetics in the University of Southern California (USC) Keck School of Medicine, working with multidisciplinary faculty collaborators in the Departments of Pediatrics, Medicine, and Preventive Medicine, in the Schools of Pharmacy and Mathematics, and the Jet Propulsion Laboratory in Pasadena, CA. With expertise in computerized drug-response modeling, he is applying his research interests to the care of his patients by operating the first HIV therapeutic drug management service at LAC+USC, which is available to all HIV providers. He also provides out- and inpatient pharmacologic consultation for a wide range of therapeutically challenging cases. In the fall of 2010, he will complete a Master’s of Science program in Clinical and Biomedical Investigations at USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling, and he has recently been appointed to the United States Food and Drug Administration Anti-infective Drug Advisory Committee. He has received NIH funding for most of his post-doctoral career, is the author of numerous papers and abstracts, and he is invited to give talks and workshops on dose individualization and optimization worldwide.

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Russell CJ, Mamey MR, Koh JY, Schrager SM, Neely M, Wu S. Length of Stay and Hospital Revisit After Bacterial Tracheostomy-Associated Respiratory Tract Infection Hospitalizations. Hosp Pediatr. 2018 Jan 16. PMID: 29339536.
        View in: PubMed
      2. Russell CJ, Thurm C, Hall M, Simon TD, Neely M, Berry JG. Risk factors for hospitalizations due to bacterial respiratory tract infections after tracheotomy. Pediatr Pulmonol. 2018 Jan 04. PMID: 29314789.
        View in: PubMed
      3. Sheng X, Parmentier JH, Tucci J, Pei H, Cortez-Toledo O, Dieli-Conwright CM, Oberley MJ, Neely M, Orgel E, Louie SG, Mittelman SD. Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin. Mol Cancer Res. 2017 Nov 08. PMID: 29117945.
        View in: PubMed
      4. Ramos-Martín V, Neely M, Padmore K, Peak M, Beresford MW, Turner MA, Paulus S, López-Herce J, Hope WW. Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. Antimicrob Agents Chemother. 2017 Oct; 61(10). PMID: 28760897.
        View in: PubMed
      5. Ramos-Martín V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, Pea F, Neely M, Hope WW. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother. 2017 Sep 11. PMID: 28962026.
        View in: PubMed
      6. Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid V, Elens L. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Front Pharmacol. 2017; 8:358. PMID: 28642710.
        View in: PubMed
      7. Kovanda LL, Kolamunnage-Dona R, Neely M, Maertens J, Lee M, Hope WW. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clin Infect Dis. 2017 Jun 01; 64(11):1557-1563. PMID: 28472247.
        View in: PubMed
      8. Russell CJ, Simon TD, Mamey MR, Newth CJL, Neely M. Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. Pediatr Pulmonol. 2017 Sep; 52(9):1212-1218. PMID: 28440922.
        View in: PubMed
      9. Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017 May; 101(5):646-656. PMID: 28182269.
        View in: PubMed
      10. Philippe M, Neely M, Bertrand Y, Bleyzac N, Goutelle S. A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. Clin Pharmacokinet. 2017 Apr; 56(4):435-447. PMID: 27585476.
        View in: PubMed
      11. Rhodes NJ, Prozialeck WC, Lodise TP, Venkatesan N, O'Donnell JN, Pais G, Cluff C, Lamar PC, Neely M, Gulati A, Scheetz MH. Correction for Rhodes et al., Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. Antimicrob Agents Chemother. 2017 Apr; 61(4). PMID: 28341810.
        View in: PubMed
      12. Suchánková H, Lipš M, Urbánek K, Neely M, Strojil J. Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017 Mar; 49(3):348-354. PMID: 28189734.
        View in: PubMed
      13. Neely M. Scalpels not hammers: The way forward for precision drug prescription. Clin Pharmacol Ther. 2017 Mar; 101(3):368-372. PMID: 27984653.
        View in: PubMed
      14. Bayard DS, Neely M. Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole[Formula: see text]. J Pharmacokinet Pharmacodyn. 2017 Apr; 44(2):95-111. PMID: 27909942.
        View in: PubMed
      15. Mathew SK, Mathew BS, Neely M, Naik GS, Prabha R, Jacob GG, K S, Fleming DH. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients. Ther Drug Monit. 2016 Oct; 38(5):593-9. PMID: 27454665.
        View in: PubMed
      16. Burris JF, Tortorici MA, Mandic M, Neely M, Reed MD. Dosage Adjustments Related to Young or Old Age and Organ Impairment. J Clin Pharmacol. 2016 Dec; 56(12):1461-1473. PMID: 27539787.
        View in: PubMed
      17. Ramos-Martín V, Neely M, McGowan P, Siner S, Padmore K, Peak M, Beresford MW, Turner MA, Paulus S, Hope WW. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. J Antimicrob Chemother. 2016 Nov; 71(11):3168-3178. PMID: 27543654.
        View in: PubMed
      18. Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, Schumitzky A, Bleyzac N, Goutelle S. Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. Ther Drug Monit. 2016 Jun; 38(3):332-42. PMID: 26829600; PMCID: PMC4864122 [Available on 06/01/17].
      19. Hope WW, Walsh TJ, Goodwin J, Peloquin CA, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely M, Wingard JR. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. J Antimicrob Chemother. 2016 Aug; 71(8):2234-40. PMID: 27121401; PMCID: PMC4954923 [Available on 08/01/17].
      20. Cattaneo D, Alffenaar JW, Neely M. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opin Drug Metab Toxicol. 2016 May; 12(5):533-44. PMID: 26982718.
        View in: PubMed
      21. Huurneman LJ, Neely M, Veringa A, Docobo Pérez F, Ramos-Martin V, Tissing WJ, Alffenaar JW, Hope W. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2336-42. PMID: 26833158; PMCID: PMC4808208 [Available on 10/01/16].
      22. Rhodes NJ, Kuti JL, Nicolau DP, Neely M, Nicasio AM, Scheetz MH. An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. J Infect Chemother. 2016 Feb; 22(2):78-83. PMID: 26712584.
        View in: PubMed
      23. Rhodes NJ, Kuti JL, Nicolau DP, Van Wart S, Nicasio AM, Liu J, Lee BJ, Neely M, Scheetz MH. Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. Antimicrob Agents Chemother. 2015 Dec 14; 60(3):1401-10. PMID: 26666929; PMCID: PMC4775983.
      24. Billat PA, Woillard JB, Essig M, Sauvage FL, Picard N, Alain S, Neely M, Marquet P, Saint-Marcoux F. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2016 Feb; 71(2):484-9. PMID: 26538506.
        View in: PubMed
      25. Størset E, Åsberg A, Skauby M, Neely M, Bergan S, Bremer S, Midtvedt K. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. Transplantation. 2015 Oct; 99(10):2158-66. PMID: 25886918; PMCID: PMC4591080 [Available on 10/01/16].
      26. Wang S, He X, Yu JY, Neely M, Zhang L, Peng L, Shi X, Li X, Wang S, Cao H, Gai Z, Huang SH. Characterisation of a multidrug-resistant meningitic Escherichia coli strain (O75:K1:H5) isolated from an infant that is sensitive to memantine, a newly identified host-directed antimicrobial drug. Int J Antimicrob Agents. 2015 Nov; 46(5):598-600. PMID: 26387615.
        View in: PubMed
      27. Lalande L, Bourguignon L, Bihari S, Maire P, Neely M, Jelliffe R, Goutelle S. Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs. Antimicrob Agents Chemother. 2015 Sep; 59(9):5181-9. PMID: 26077251; PMCID: PMC4538517.
      28. Jelliffe RW, Schumitzky A, Bayard D, Fu X, Neely M. Describing Assay Precision-Reciprocal of Variance Is Correct, Not CV Percent: Its Use Should Significantly Improve Laboratory Performance. Ther Drug Monit. 2015 Jun; 37(3):389-94. PMID: 25970509; PMCID: PMC4435937.
      29. Neely M, Louie S, Xu J, Anthony P, Thuvamontolrat K, Mordwinkin N, Kovacs A. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy. J Clin Pharmacol. 2015 Jul; 55(7):798-808. PMID: 25683232; PMCID: PMC4461473.
      30. Rhodes NJ, Gardiner BJ, Neely M, Grayson ML, Ellis AG, Lawrentschuk N, Frauman AG, Maxwell KM, Zembower TR, Scheetz MH. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother. 2015 Jul; 70(7):2068-73. PMID: 25802286.
        View in: PubMed
      31. Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, Orbach R, Liu S, Louie S, Hope W. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015; 59(6):3090-7. PMID: 25779580; PMCID: PMC4432122.
      32. Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely M, Goutelle S. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrob Agents Chemother. 2015; 59(6):2986-94. PMID: 25753640; PMCID: PMC4432143.
      33. Louie A, Liu W, VanGuilder M, Neely M, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. J Infect Dis. 2015 Apr 15; 211(8):1326-33. PMID: 25362196; PMCID: PMC4447837.
      34. Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, Marquet P, Saint-Marcoux F. Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. Br J Clin Pharmacol. 2014 Oct; 78(4):836-46. PMID: 24698009; PMCID: PMC4239977.
      35. Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies DL. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport. 2014 Sep 10; 25(13):1018-23. PMID: 25004078; PMCID: PMC4126080.
      36. Neely M, Kaplan EL, Blumer JL, Faix DJ, Broderick MP. A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults. Antimicrob Agents Chemother. 2014 Nov; 58(11):6735-41. PMID: 25182635; PMCID: PMC4249386.
      37. Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One. 2014; 9(7):e101311. PMID: 25003557; PMCID: PMC4086932.
      38. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014 Nov 20; 77:50-7. PMID: 24910345.
        View in: PubMed
      39. Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely M, Hope WW. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014 Jul; 58(7):4094-102. PMID: 24798288; PMCID: PMC4068511.
      40. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely M, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun; 14(6):498-509. PMID: 24768475; PMCID: PMC4181663.
      41. Kinney ME, Lamberski N, Wack R, Foster R, Neely M, Tell L, Gehring R. Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (Gopherus agassizii). J Vet Pharmacol Ther. 2014 Oct; 37(5):500-7. PMID: 24611596.
        View in: PubMed
      42. Goutelle S, Bourguignon L, Maire P, Jelliffe RW, Neely M. The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy. Curr Pharm Des. 2014; 20(39):6191-206. PMID: 25190098.
        View in: PubMed
      43. Atrio J, Stanczyk FZ, Neely M, Cherala G, Kovacs A, Mishell DR. Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. J Acquir Immune Defic Syndr. 2014 Jan 01; 65(1):72-7. PMID: 24025339; PMCID: PMC3946363.
      44. Tatarinova T, Kryshchenko A, Triska M, Hassan M, Murphy D, Neely M, Schumitzky A. NPEST: a nonparametric method and a database for transcription start site prediction. Quant Biol. 2013 Dec; 1(4):261-271. PMID: 25197613.
        View in: PubMed
      45. Neely M, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014; 58(1):309-16. PMID: 24165176; PMCID: PMC3910745.
      46. Åsberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014 Feb; 18(1):103-11. PMID: 24152053; PMCID: PMC3880615.
      47. Åsberg A, Midtvedt K, van Guilder M, Størset E, Bremer S, Bergan S, Jelliffe R, Hartmann A, Neely M. Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. Transpl Int. 2013 Dec; 26(12):1198-207. PMID: 24118301; PMCID: PMC3852421.
      48. Loo AS, Neely M, Anderson EJ, Ghossein C, McLaughlin MM, Scheetz MH. Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis. Antimicrob Agents Chemother. 2013 Dec; 57(12):5854-9. PMID: 24018264; PMCID: PMC3837845.
      49. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely M, Hope WW. Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013 Dec; 57(12):5811-9. PMID: 24002098; PMCID: PMC3837869.
      50. Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A, Wiegand R, Wheeling T, Bohannon B, Dominguez K. Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. Pediatr Infect Dis J. 2013 Sep; 32(9):e370-6. PMID: 24008749; PMCID: PMC3766529.
      51. O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely M, Harrison TS, Perfect JR, Hope WW. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infect Dis. 2013 Jul 15; 208(2):351-61. PMID: 23599314; PMCID: PMC3685229.
      52. Tatarinova T, Neely M, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe R, Leary R, Chubatiuk A, Schumitzky A. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. J Pharmacokinet Pharmacodyn. 2013 Apr; 40(2):189-99. PMID: 23404393; PMCID: PMC3630269.
      53. Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, Neely M. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013 Apr; 57(4):1888-94. PMID: 23380734; PMCID: PMC3623322.
      54. Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, Kiss A, Neely M. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb; 115(2):224-32. PMID: 23246224; PMCID: PMC3545087.
      55. Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012 Oct 03; 1:e9. PMID: 23887364; PMCID: PMC3603431.
      56. Schaudinn C, Gorur A, Webster P, Jones AC, Neely M, Jelliffe RW, Le AD, Sedghizadeh PP. Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct; 114(4):480-6. PMID: 22986243.
        View in: PubMed
      57. Neely M, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012 Aug; 34(4):467-76. PMID: 22722776; PMCID: PMC3394880.
      58. Montoya JG, Neely M, Gupta S, Lunn MR, Loomis KS, Pritchett JC, Polsky B, Medveczky PG. Antiviral therapy of two patients with chromosomally-integrated human herpesvirus-6A presenting with cognitive dysfunction. J Clin Virol. 2012 Sep; 55(1):40-5. PMID: 22770640.
        View in: PubMed
      59. Rakhmanina NY, Neely M, Capparelli EV. High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count. Ther Drug Monit. 2012 Jun; 34(3):237-41. PMID: 22549499; PMCID: PMC3354040.
      60. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely M, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012 May; 129(5):e1343-7. PMID: 22492761.
        View in: PubMed
      61. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother. 2012 Jun; 56(6):2959-66. PMID: 22371894; PMCID: PMC3370715.
      62. Charhon N, Neely M, Bourguignon L, Maire P, Jelliffe RW, Goutelle S. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob Agents Chemother. 2012 Apr; 56(4):1862-9. PMID: 22290966; PMCID: PMC3318363.
      63. Neely M, Louie S. Obesity and its impact on drug therapy: are we ready for this change? Clin Pharmacokinet. 2011 Dec 01; 50(12):825-6. PMID: 22087869.
        View in: PubMed
      64. Bulitta JB, Landersdorfer CB, Forrest A, Brown SV, Neely M, Tsuji BT, Louie A. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol. 2011 Dec; 12(12):2044-61. PMID: 21554212.
        View in: PubMed
      65. Schein R, Homans J, Larsen RA, Neely M. Posaconazole for chronic refractory coccidioidal meningitis. Clin Infect Dis. 2011 Dec; 53(12):1252-4. PMID: 21987729.
        View in: PubMed
      66. Florescu DF, Pergam SA, Neely M, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012 May; 18(5):731-8. PMID: 21963623; PMCID: PMC3608125.
      67. Goutelle S, Neely M, Bleyzac N. Comment: assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011 Sep; 45(9):1171-2. PMID: 21862712.
        View in: PubMed
      68. Rakhmanina NY, Neely M, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Ther Drug Monit. 2011 Aug; 33(4):417-24. PMID: 21743379; PMCID: PMC3139013.
      69. Jelliffe R, Neely M, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Bustad A, Laing D, Yamada W, Bartroff J, Tatarinova T. Nonparametric population modeling and Bayesian analysis. Pharmacol Res. 2011 Oct; 64(4):426. PMID: 21699981.
        View in: PubMed
      70. Neely M, Rakhmanina NY. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents. Clin Pharmacokinet. 2011 Mar; 50(3):143-89. PMID: 21294595.
        View in: PubMed
      71. Festekjian A, Neely M. Incidence and predictors of invasive candidiasis associated with candidaemia in children. Mycoses. 2011 Mar; 54(2):146-53. PMID: 19821906; PMCID: PMC2888996.
      72. Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. 2011 May; 12(5):531-8. PMID: 21277838; PMCID: PMC3086992.
      73. Garvie PA, Flynn PM, Belzer M, Britto P, Hu C, Graham B, Neely M, McSherry GD, Spector SA, Gaur AH. Psychological factors, beliefs about medication, and adherence of youth with human immunodeficiency virus in a multisite directly observed therapy pilot study. J Adolesc Health. 2011 Jun; 48(6):637-40. PMID: 21575827; PMCID: PMC3096841.
      74. Neely M, Decosterd L, Fayet A, Lee JS, Margol A, Kanani M, di Iulio J, von Schoen-Angerer T, Jelliffe R, Calmy A. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010 Nov; 54(11):4619-25. PMID: 20823282; PMCID: PMC2976128.
      75. Gaur AH, Belzer M, Britto P, Garvie PA, Hu C, Graham B, Neely M, McSherry G, Spector SA, Flynn PM. Directly observed therapy (DOT) for nonadherent HIV-infected youth: lessons learned, challenges ahead. AIDS Res Hum Retroviruses. 2010 Sep; 26(9):947-53. PMID: 20707731; PMCID: PMC2957634.
      76. Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely M. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010 Jun; 32(3):273-81. PMID: 20445485; PMCID: PMC2886015.
      77. Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol. 2010 Jul; 50(7):842-7. PMID: 20154293.
        View in: PubMed
      78. Neely M, Rakhmanina NY. Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children. J Antimicrob Chemother. 2010 Apr; 65(4):808-9; author reply 809-10. PMID: 20086000.
        View in: PubMed
      79. Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis. 2010 Jan 01; 50(1):27-36. PMID: 19951112; PMCID: PMC2803104.
      80. Neely M, Kovacs A. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. Ther Clin Risk Manag. 2009 Jun; 5(3):595-615. PMID: 19707276; PMCID: PMC2724190.
      81. Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely M. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009 Jun; 53(6):2532-8. PMID: 19258274; PMCID: PMC2687254.
      82. Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009 Apr; 53(4):1450-6. PMID: 19114680; PMCID: PMC2663098.
      83. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008 Sep; 48(9):1081-91. PMID: 18635757; PMCID: PMC2724306.
      84. Neely M, Benning L, Xu J, Strickler HD, Greenblatt RM, Minkoff H, Young M, Bremer J, Levine AM, Kovacs A. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):38-42. PMID: 17106279; PMCID: PMC3126662.
      85. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely M, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov; 49(11):4536-45. PMID: 16251293; PMCID: PMC1280172.
      86. Neely M, Kovacs A. Management of antiretroviral therapy in neonates, children, and adolescents. Curr HIV/AIDS Rep. 2004 Jun; 1(2):97-104. PMID: 16091229.
        View in: PubMed
      87. Neely M, Kovacs A. Management of Antiretroviral Therapy in Neonates, Children, and Adolescents. Curr Infect Dis Rep. 2003 Dec; 5(6):521-530. PMID: 14642195.
        View in: PubMed
      88. Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003 Aug; 3(2):61-7. PMID: 12913796; PMCID: PMC2141601.
      89. Neely M, Blumer J. Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients. Curr Ther Res Clin Exp. 2003 Feb; 64(2):127-36. PMID: 24944361; PMCID: PMC4053026.
      90. Neely M, Toltzis P. Infection control in pediatric hospitals. Curr Opin Infect Dis. 2001 Aug; 14(4):449-53. PMID: 11964864.
        View in: PubMed
      91. Neely M, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics. 2001 Feb; 107(2):404-5. PMID: 11158475.
        View in: PubMed
      92. Neely M, Ghannoum MA. The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis. 2000 Dec; 19(12):897-914. PMID: 11205627.
        View in: PubMed